Mink Therapeutics, INC. (INKT) — 8-K Filings

8-K Filings (21)

• 8-K Filing — Dec 8, 2025
• MiNK Therapeutics Relocates HQ to New York — Sep 29, 2025 Risk: low
  MiNK Therapeutics, Inc. announced on September 23, 2025, a change in its principal executive offices to 149 Fifth Avenue, Suite 500, New York, NY 10010. The com
• MiNK Therapeutics Files 8-K on Operations and Financials — Aug 14, 2025 Risk: low
  MiNK Therapeutics, Inc. filed an 8-K on August 14, 2025, reporting on its results of operations and financial condition. The filing also includes financial stat
• MiNK Therapeutics Files 8-K with Material Agreement — Jul 15, 2025 Risk: medium
  On July 15, 2025, MiNK Therapeutics, Inc. filed an 8-K report. The filing indicates the company entered into a material definitive agreement and also includes f
• MiNK Therapeutics to be Acquired by 03 Life Sciences — Jul 14, 2025 Risk: medium
  MiNK Therapeutics, Inc. announced on July 11, 2025, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is expec
• MiNK Therapeutics Files 8-K on Shareholder Vote Matters — Jun 18, 2025 Risk: low
  MiNK Therapeutics, Inc. filed an 8-K on June 18, 2025, to report on matters submitted to a vote of its security holders. The company, formerly known as AgenTus
• MiNK Therapeutics Files 8-K on Financials — May 15, 2025 Risk: low
  MiNK Therapeutics, Inc. filed an 8-K on May 15, 2025, reporting on its Results of Operations and Financial Condition, and including Financial Statements and Exh
• MiNK Therapeutics Files 8-K — Mar 18, 2025 Risk: low
  On March 18, 2025, MiNK Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 149 Fifth Avenue,
• MiNK Therapeutics Files 8-K with Corporate Updates — Jan 21, 2025 Risk: low
  MiNK Therapeutics, Inc. filed an 8-K on January 21, 2025, reporting events as of January 17, 2025. The filing indicates amendments to articles of incorporation
• MiNK Therapeutics Files 8-K on Financials — Nov 14, 2024 Risk: low
  MiNK Therapeutics, Inc. filed an 8-K on November 14, 2024, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and E
• MiNK Therapeutics Appoints New Chief Medical Officer — Oct 31, 2024 Risk: medium
  MiNK Therapeutics, Inc. announced on October 30, 2024, the appointment of Dr. Jonathan G. Drachman as Chief Medical Officer. Dr. Drachman previously served as C
• MiNK Therapeutics Appoints New CMO, Elects Director — Oct 18, 2024 Risk: medium
  MiNK Therapeutics, Inc. announced on October 15, 2024, the appointment of Dr. Jonathan G. Drachman as Chief Medical Officer and the election of Dr. Jennifer L.
• MiNK Therapeutics Faces Delisting Concerns — Sep 13, 2024 Risk: high
  MiNK Therapeutics, Inc. filed an 8-K on September 13, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company was form
• MiNK Therapeutics Faces Nasdaq Delisting Warning — Aug 30, 2024 Risk: high
  MiNK Therapeutics, Inc. announced on August 27, 2024, that it received a notification from the Nasdaq Stock Market indicating non-compliance with listing rules.
• MiNK Therapeutics Files 8-K on Operations and Financials — Aug 13, 2024 Risk: low
  MiNK Therapeutics, Inc. filed an 8-K on August 13, 2024, reporting on its results of operations and financial condition. The filing also includes financial stat
• MiNK Therapeutics Files 8-K on Shareholder Votes — Jun 17, 2024 Risk: low
  MiNK Therapeutics, Inc. filed an 8-K on June 17, 2024, reporting on matters submitted to a vote of security holders as of June 12, 2024. The company, formerly k
• MiNK Therapeutics Files 8-K for Equity Sale — May 16, 2024 Risk: medium
  MiNK Therapeutics, Inc. entered into a Material Definitive Agreement on May 13, 2024, related to the unregistered sale of equity securities. The company, former
• MiNK Therapeutics Files 8-K on Financials — May 14, 2024 Risk: low
  MiNK Therapeutics, Inc. filed an 8-K on May 14, 2024, reporting on its results of operations and financial condition. The filing also includes financial stateme
• MiNK Therapeutics Files 8-K on Financials — Mar 21, 2024 Risk: low
  MiNK Therapeutics, Inc. filed an 8-K on March 21, 2024, reporting on its results of operations and financial condition. The filing also includes financial state
• MiNK Therapeutics Faces Nasdaq Delisting Warning — Feb 29, 2024 Risk: high
  MiNK Therapeutics, Inc. received a notice on February 23, 2024, indicating it failed to meet the minimum bid price requirement for continued listing on the Nasd
• MiNK Therapeutics Reports New Material Agreement & Financial Obligation — Feb 14, 2024 Risk: medium
  MiNK Therapeutics, Inc. filed an 8-K on February 14, 2024, reporting an event that occurred on February 12, 2024. The filing indicates the company entered into

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX